Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of ...

has seen its profile rise with the development of XHANCE, a corticosteroid drug-device combination nasal spray. XHANCE is the first and only approved treatment for patients with chronic ...

Efforts to develop next-generation vaccines are underway, such as nasal vaccines that researchers hope might do a better job of blocking infection. Genetic changes called mutations happen as ...

It is important to understand how tanning nasal sprays work, their possible side effects, and safer ways to achieve a tan. Tanning nasal spray contains what is known as melanotan II, an ingredient ...

Sunscreen is available in multiple formats, including lotions and sprays. Lotions and sprays can be effective if used properly. However, applying enough spray to all needed areas can be difficult.

The company also revised its 2024 sales forecast for Xhance, its nasal spray treatment, to a range of $75 million to $79 million. Despite the revised sales forecast, OptiNose reported a 3% year ...